On September 8, 2021 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at the European Society for Medical Oncology Congress 2021 (Press release, Coherus Biosciences, SEP 8, 2021, View Source [SID1234587453]). A real-world study comparing same-day and next-day administration of pegfilgrastim will be the topic of a poster presentation at the ASCO (Free ASCO Whitepaper) Quality Care Symposium on September 25. In addition, an oral presentation at the 54th Annual Scientific Meeting of the Retina Society on October 1 will highlight clinical data from the CHS-201 (also known as FYB201) program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IASLC 2021 World Conference on Lung Cancer (WCLC)

Mini-oral presentation: "CHOICE-01: A Phase 3 Study of Toripalimab versus Placebo in Combination with First-Line Chemotherapy for Advanced NSCLC" (Session #MA13)
Professor Jie Wang, MD, PhD, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, will present the interim results of the CHOICE-01 study detailed in the abstract published by WCLC on August 18, 2021.
Presentation time: September 13 at 8:10 p.m. Eastern Time
European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2021

Mini-oral presentation: "JUPITER-06: A Randomized, Double-blind, Phase 3 Study of Toripalimab versus Placebo in Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)" (Abstract #1373MO)
Dr. Ruihua Xu, President and Professor, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, will present interim results of the JUPITER-06 trial. ESMO (Free ESMO Whitepaper) will release the JUPITER-06 abstract at 6:05 p.m. Eastern Time on September 16.
Presentation time: September 17 at 12:05 p.m. Eastern Time
ASCO Quality Care Symposium

Poster presentation: "Real-world comparison of febrile neutropenia rates with same-day versus next-day administration of pegfilgrastim" (Abstract #299)
Kyle Kitchen, PharmD, Director of Pharmacy Services, Utah Cancer Specialists
Poster Session B: September 25 at 7 a.m. Eastern Time
The 54th Annual Scientific Meeting of the Retina Society

Oral presentation: "Columbus-AMD: Efficacy and Safety of FYB201, a Proposed Biosimilar to Ranibizumab, in Neovascular AMD (nAMD)"
Dr. Peter Kaiser, Professor of Ophthalmology, Cole Eye Institute of the Cleveland Clinic
Presentation Time: October 1 at 3:32 p.m. Eastern Time